Cingulate Inc. announced the appointment of Bryan Downey as Chief Commercial Officer. This leadership change comes as the company prepares for the potential commercialization of its lead product, CTx-1301, pending FDA approval.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cingulate Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572107-en) on November 10, 2025, and is solely responsible for the information contained therein.
Comments